The PPARγ agonist rosiglitazone, an approved drug for type 2 diabetes, exerts inhibitory effects on pituitary tumour growth, tumour ACTH synthesis, and secretion.43 The gene discussed is POMC; the disease is type 2 diabetes mellitus.